Fremanezumab-vfrm, a humanized monoclonal antibody that binds to calcitonin gene–related peptide (CGRP) ligand and blocks its binding to the receptor, is the first and only anti-CGRP treatment for the prevention of migraine with quarterly (675 mg) and monthly (225 mg) dosing options, which are available in prefilled syringes. Fremanezumab-vfrm can be administered in
To read the full story, Log in or Sign up for a Free Account
We've added an exciting new feature to our website. Click on "Clinical" in the navbar to explore!
The following result is from the NPI Registry Public Search database. You can click on the NPI number to view detailed information and verify its accuracy. If your NPI is not found in this search, you can try searching again using the form below. If you have difficulty finding your NPI number please contact us at web@mcmahonmed.com
